NSE: ALIVUS | BSE: 543322

Strong Performer, Getting Expensive

Download real time

1386.80 -3.40 (-0.24%)

69.33% Gain from 52W Low

80,563 NSE+BSE Volume

NSE 11 Sep, 2026 3:31 PM (IST)

17,025.9

Market Cap

High in industry

Beta 1Year

Very Low volatility

Alivus Life Sciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALIVUS, BSE:543322 Alivus Life Sciences Ltd.

Search Inside the pdf :

Alivus Life Sciences Ltd.

15 May 2026

1386.80

-0.24%

Alivus Life Sciences

Buy: Alivus Life Sciences Ltd.

Target

ICICI Direct

leading developer and manufacturer of APIs (~93% of FY25 revenues) with major focus in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. GLS caters to over 700 customers...

Alivus Life Sciences has gained 32.62% in the last 3 Months

Alivus Life Sciences Ltd.

23 Jan 2026

1386.80

-0.24%

Alivus Life Science

Buy: Alivus Life Sciences Ltd.

Target

ICICI Direct

About the stock: Alivus life sciences (erstwhile Glenmark life sciences) is a leading developer and manufacturer of APIs (~93% of FY25 revenues) with major focus in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. GLS caters to over 700 customers...

Alivus Life Sciences has gained 47.63% in the last 6 Months

Alivus Life Sciences Ltd.

07 Nov 2025

1386.80

-0.24%

Alivus Life Science

Buy: Alivus Life Sciences Ltd.

Target

ICICI Direct

Well prepated for a long term sustainable growth developer and manufacturer of APIs (~93% of FY25 revenues) with major focus in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. GLS caters to over 700 customers in more...

Alivus Life Sciences has gained 48.02% in the last 1 Year

Alivus Life Sciences Ltd.

18 Mar 2025

1386.80

-0.24%

BP Equities Alivus lifesciences Initiating Coverage BUY Target 1,317

Buy: Alivus Life Sciences Ltd.

BP Wealth

Alivus Life Sciences has gained 48.02% in the last 1 Year

Alivus Life Sciences Ltd.

26 Aug 2024

1386.80

-0.24%

Glenmark Life Science

Buy: Alivus Life Sciences Ltd.

Target

ICICI Direct

Alivus Life Sciences Ltd. is trading above all available SMAs

Alivus Life Sciences Ltd.

16 Jul 2024

1386.80

-0.24%

Glenmark Life Sciences Ltd

Buy: Alivus Life Sciences Ltd.

Hem Securities

Alivus Life Sciences.. has an average target of 1235.00 from 1 broker.

Alivus Life Sciences Ltd.

29 Apr 2024

1386.80

-0.24%

First Light | Maruti Suzuki, Hindustan Unilever, Bajaj Finance, SBI Life, Supreme Industries, Dalmia Bharat, UTI AMC, Glenmark Life Sciences

Hold: Alivus Life Sciences Ltd.

Target

BOB Capital Markets Ltd.

MSIL: Steady performance, but steep valuations; downgrade to HOLD. HUVR: Subdued performance; expect gradual recovery. BAF: Obstacles for a powerful player on a protracted journey. SBILIFE: Expect market dominance to continue. SI: In-line Q4FY24; pipe volume guided to grow at healthy rate in FY25. DALBHARA: Disappointments all over; but paving the way for growth. UTIAM: Core profit in line; maintain HOLD. GLS: Weak quarter; maintain HOLD